← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,282	-31	-1%	$186B
2	2 Danaher DHR $158B	2,012	-29	-1%	$144B
3	3 Novartis NVS $279B	1,141	+4	+0.4%	$16.9B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,064	-31	-3%	$55B
5	5 Illumina ILMN $41B	911	-130	-12%	$25.3B
6	6 Agilent Technologies A $49.1B	886	-47	-5%	$30.6B
7	7 Charles River Laboratories CRL $14.4B	627	-17	-3%	$10.4B
8	8 Revvity RVTY $17B	584	-58	-9%	$15.7B
9	9 DELISTED CATALENT, INC. CTLT	544	+8	+1%	$19.7B
10	10 CRISPR Therapeutics CRSP $4.86B	435	-11	-2%	$3.35B
11	11 Alnylam Pharmaceuticals ALNY $30B	423	-21	-5%	$16.6B
12	12 Azenta AZTA $1.63B	372	-11	-3%	$5.51B
13	13 Ionis Pharmaceuticals IONS $7.1B	350	+16	+5%	$4.61B
14	14 ARK Genomic Revolution ETF ARKG $2.05B	334	-54	-14%	$629M
15	15 Guardant Health GH $21.9B	332	-24	-7%	$3.75B
16	16 Sarepta Therapeutics SRPT $1.78B	332	+3	+0.9%	$5.5B
17	17 Intellia Therapeutics NTLA $1.6B	301	-48	-14%	$3.44B
18	18 Bruker BRKR $8.47B	296	-15	-5%	$6.51B
19	19 Qiagen QGEN $9.41B	288	-5	-2%	$6.11B
20	NVTA 20 DELISTED Invitae Corporation NVTA	286	-30	-9%	$547M
21	21 Arrowhead Research ARWR $8.25B	278	-29	-9%	$2.54B
22	22 Fulgent Genetics FLGT $578M	262	-13	-5%	$711M
23	23 Ginkgo Bioworks DNA $776M	260	+70	+37%	$1.93B
24	24 Editas Medicine EDIT $349M	257	+1	+0.4%	$562M
25	25 10x Genomics TXG $9.52B	254	-60	-19%	$3.91B